Form 4: Merck Director Christine Seidman Acquires Over 2,800 Phantom Stock Units

Merck & Co., Inc. Director Christine E. Seidman has acquired 2,863.0921 phantom stock units as part of a deferred compensation plan, aligning her interests with the company's performance.

Summary

• Christine E. Seidman, a Director at Merck & Co., Inc. (MRK), acquired 2,863.0921 phantom stock units on May 30, 2025.
• These phantom stock units were acquired at a value of $76.84 per unit.
• The phantom stock units are convertible on a 1-for-1 basis to common stock.
• The units are to be settled 100% in cash upon Ms. Seidman's termination of service, in accordance with a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation.
• Following this transaction, Ms. Seidman beneficially owns a total of 18,393.2387 phantom stock units.
• Her holdings also include 100 shares of Common Stock held directly.
• The reported phantom stock holdings include units acquired through dividend reinvestment transactions.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates a director's continued alignment with the company's performance through a compensation award, which is a routine and expected event for corporate governance.

Positives

• The acquisition of phantom stock units by a director aligns their financial interests with the long-term performance of Merck & Co., Inc.
• The transaction is part of a structured deferred compensation plan, indicating a standard and expected form of executive remuneration.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider transaction, specifically a director's compensation award. It does not provide broader industry context or trends, but rather details a specific compensation event within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The acquisition of phantom stock units by a director helps align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term company value.

Key Dates

Keywords

Merck & Co. Inc., MRK, SEC Form 4, insider transaction, director compensation, phantom stock, equity award, deferred compensation